Please login to the form below

Not currently logged in
Email:
Password:

GSK's Avandia study halted by FDA

The US Food and Drug Administration has asked GlaxoSmithKline to suspend enrolment in a postmarketing study of diabetes drug Avandia

The US Food and Drug Administration (FDA) has asked GlaxoSmithKline (GSK) to suspend enrolment in a post-marketing clinical study of the company's controversial diabetes drug Avandia (rosiglitazone).

The FDA's "partial clinical hold" suspends enrolment of new patients in the trial while the federal agency reviews the recommendations made by outside experts last week during a joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. Patients who have already been enrolled will continue in the study.

The trial, called Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE), is designed to compare the cardiovascular safety of Avandia with Takeda's diabetes drug Actos (pioglitazone hydrochlorid). At the advisory committee meeting, panel members voted 21-to-four that Avandia is more likely than Actos to cause a heart attack. 

"GSK will work with the TIDE Steering Committee to send a summary of recent safety data and a summary of the FDA Advisory Committee meeting on Avandia to all TIDE investigators and Institutional Review Boards to ensure they have the latest information for patients," the company said.

The panel members voted last week 19-to-11 to recommend that the TIDE study continue if Avandia stays on the market. The study had originally been mandated by the FDA.

The two advisory committees voted 20-to-12 at the meeting to recommend that the federal agency allow Avandia to stay on the market in spite of concerns about the risk of heart attack and stroke. Most of the advisors who favoured allowing continued marketing of the drug also pushed for new warnings and restrictions.

22nd July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics